Financing

Machine learning concept
#Artificial intelligence (AI) #Financing #Oncology #Orakl Oncology #Spinout #Start-ups

€11m supports launch of AI-powered drug development platform

Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors.   The new funding will be used to accelerate the company's growth and support the launch of two new commercial products, O-Predict and O-Validate… Read More

#Business & Investment #News #Start-up Zone

Antibody drug conjugate
#Allink Biotherapeutics #Antibody drug conjugate (ADC) #Bispecific Antibodies #Financing

Allink raises $42m for bispecific antibody and ADC pipeline

Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing.   The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine Capital.  "Since our… Read More

#Business & Investment #News

#Adcendo #Antibody drug conjugate (ADC) #Financing #Fundraising

Adcendo raises $135 million to advance ADC pipeline

Biotech company Adcendo has announced the successful closing of an oversubscribed $135 million Series B financing round.   Proceeds from the fundraise will be used to accelerate the development of the company's ADC pipeline, including the ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05 and A0401 programmes.  The financing round was… Read More

#Business & Investment #News

GBP pound sterling funding
#Antibiotic resistance #Antimicrobial resistance (AMR) #Financing #Funding #Glox Therapeutics

£1 million PACE grant to accelerate precision antibiotics 

Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.   The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli… Read More

#Business & Investment #News

#Bill & Melinda Gates Foundation #Export and Investment Fund of Denmark (EIFO) #Financing #Freya Biosciences #Women's health

Over $10.4 million invested in women’s and infant health drug 

Women’s health biotech Freya Biosciences has received a $10.4 million strategic investment from the Bill & Melinda Gates Foundation with $1.4 million additional financing from current investor Export and Investment Fund of Denmark (EIFO).  The funds will be used to develop microbial immunotherapies for the treatment of bacterial vaginosis (BV)… Read More

#Business & Investment #News

#Cell therapy #Financing #Oncology #Phase I trial #Vittoria Biotherapeutics

Vittoria raises $25 million to accelerate T cell therapies

Immunotherapy company Vittoria Biotherapeutics has successfully completed a $25 million private financing round. This funding is a $10 million extension to its previous $15 million financing secured in November 2023. The latest round was led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch… Read More

#Business & Investment #News

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which targets advanced or… Read More

#Business & Investment #News

Gene therapy
#CNS #Financing #Gene therapy #Neurogene #Private investment

Oversubscribed $200m private placement for gene therapy company

Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million. Neurogene is developing approaches and treatments which it hopes will address the limitations of conventional gene therapy in central… Read More

#Business & Investment #News

#Financing #Oncology #Radioligand Therapies (RLTs) #Radiopharmaceuticals #Starget Pharma #Start-ups

Starget secures $5.1m for clinical trial of targeted cancer therapy

Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. The funds will support… Read More

#Business & Investment #News #Start-up Zone

CAR-T cell therapy
#CAR-T #Cell therapy #Financing #Fundraising #Haematology #March Biosciences #Oncology

March Bio raises $28.4m for autologous CAR-T therapy

Biotechnology company March Biosciences (March Bio) has announced the close of a $28.4 million oversubscribed Series A financing, having raised over $51 million to date. Mission BioCapital and 4BIO Capital led the financing, with participation from KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, and Mansueto Investments. Existing investors… Read More

#Business & Investment #News

AI concept
#Artificial intelligence (AI) #Collaboration #Financing #Generative AI #Machine learning

AI-powered drug discovery continues to attract investment

Optimism around the potential role for artificial intelligence (AI) in drug discovery continues, with recent financial deals supporting its use in developing therapeutics for age-related diseases, GPCR-targeting antibodies, DUB-modulating compounds, and novel fusion proteins. AI simulation to advance therapeutics for age-related diseases Biotech Shift Bioscience has raised $16 (£12.5) million… Read More

#Business & Investment #News

Kidneys
#Financing #Gene therapy #Kidney disease #Purespring Therapeutics

Financing to transform the treatment of kidney diseases

Purespring Therapeutics, a gene therapy company focused on the treatment of kidney diseases, has raised £80 ($105) million in Series B financing. The oversubscribed round was led by Sofinnova Partners, in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona. Read More

#News

#Cystic fibrosis #Financing #Funding #Neuroscience #Oncology #Rare disease

This week in drug discovery (30 Sept – 4 Oct) 

News round-up for 30 Sept – 4 Oct by DDW Senior Digital Content Editor Diana Spencer. The theme of the news highlights this week is funding, with companies raising considerable levels of private investment, alongside new funding grants to advance the development of therapeutics for lung infections in… Read More

#News

Neuronal inclusions in Huntington’s disease
#Financing #Huntington's disease #LoQus23 Therapeutics #Neurodegenerative disorders

New therapy for Huntington’s disease gets £35 million boost

Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing. The financing round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion General Partner Rogier Rooswinkel will join LoQus23’s Board of Directors. LoQus23 was founded… Read More

#Business & Investment #News

#Biology #Cell and gene therapy #Cell therapy #Financing #Harvard Medical School #iPSC

Cell therapy company GC Therapeutics launches with $75m 

GC Therapeutics (GCTx) has launched with $75 million in total capital.  GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome (Transcription-Factor-ome), was invented and developed by scientists in the lab of Professor George Church at Harvard Medical School and the Wyss Institute.  It integrates synthetic biology, gene editing, cell engineering… Read More

#Business & Investment #News

#Draupnir Bio #Financing #Fundraising #Protein degradation

€12 million raised for extracellular protein degradation research

Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD). TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to… Read More

#Business & Investment #News